BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,774,000 | -3.6% | 11,550,000 | -4.2% | 1.28% | +10.8% |
| Q2 2023 | $84,867,200 | -2.3% | 12,055,000 | +15.7% | 1.15% | -10.6% |
| Q1 2023 | $86,902,800 | -16.4% | 10,420,000 | +15.1% | 1.29% | -17.1% |
| Q4 2022 | $103,894,000 | -8.9% | 9,050,000 | 0.0% | 1.55% | -26.3% |
| Q3 2022 | $114,030,000 | +65.8% | 9,050,000 | +39.2% | 2.11% | +55.0% |
| Q2 2022 | $68,770,000 | +125.6% | 6,500,000 | +246.7% | 1.36% | +144.0% |
| Q1 2022 | $30,488,000 | +1722.4% | 1,875,000 | +450.1% | 0.56% | +415.7% |
| Q4 2017 | $1,673,000 | -82.0% | 340,821 | -80.8% | 0.11% | -85.1% |
| Q3 2017 | $9,319,000 | -14.2% | 1,778,525 | -9.0% | 0.72% | -47.3% |
| Q2 2017 | $10,862,000 | -19.3% | 1,953,525 | +21.9% | 1.37% | -20.2% |
| Q1 2017 | $13,465,000 | +30.4% | 1,603,001 | -1.7% | 1.72% | -17.5% |
| Q4 2016 | $10,327,000 | +69.8% | 1,631,502 | +18.3% | 2.09% | +95.5% |
| Q3 2016 | $6,083,000 | – | 1,379,402 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |